Patient-derived glioblastoma organoids reflect tumor heterogeneity and treatment sensitivity
Neuro-Oncology Advances · 01.01.2023 · 5 (1)
DOI: 10.1093/noajnl/vdad152 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neuro-Oncology Advances, online erschienen am 25.11.2023. Verfasst von Maikel Verduin und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology (Maastro), GROW School for Oncology and Reproduction, Maastricht University Medical Centre, Maastricht, The Netherla…. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: FWO, KWF Kankerbestrijding, Stichting STOPhersentumoren.nl.
Abstract (Originalsprache)
Background
Treatment resistance and tumor relapse are the primary causes of mortality in glioblastoma (GBM), with intratumoral heterogeneity playing a significant role. Patient-derived cancer organoids have emerged as a promising model capable of recapitulating tumor heterogeneity. Our objective was to develop patient-derived GBM organoids (PGO) to investigate treatment response and resistance.
Methods
GBM samples were used to generate PGOs and analyzed using whole-exome sequencing (WES) and single-cell karyotype sequencing. PGOs were subjected to temozolomide (TMZ) to assess viability. Bulk RNA sequencing was performed before and after TMZ.
Results
WES analysis on individual PGOs cultured for 3 time points (1–3 months) showed a high inter-organoid correlation and retention of genetic variants (range 92.3%–97.7%). Most variants were retained in the PGO compared to the tumor (range 58%–90%) and exhibited similar copy number variations. Single-cell karyotype sequencing demonstrated preservation of genetic heterogeneity. Single-cell multiplex immunofluorescence showed maintenance of cellular states. TMZ treatment of PGOs showed a differential response, which largely corresponded with MGMT promoter methylation. Differentially expressed genes before and after TMZ revealed an upregulation of the JNK kinase pathway. Notably, the combination treatment of a JNK kinase inhibitor and TMZ demonstrated a synergistic effect.
Conclusions
Overall, these findings demonstrate the robustness of PGOs in retaining the genetic and phenotypic heterogeneity in culture and the application of measuring clinically relevant drug responses. These data show that PGOs have the potential to be further developed into avatars for personalized adaptive treatment selection and actionable drug target discovery and as a platform to study GBM biology.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiation Oncology (Maastro), GROW School for Oncology and Reproduction, Maastricht University Medical Centre, Maastricht, The Netherlands.
- Laboratory for Precision Cancer Medicine, Translational Cell and Tissue Research Unit, Department of Imaging and Pathology, KU Leuven, Leuven, Belgium.
- LISCO-KU Leuven Institute for Single Cell Omics, KU Leuven, Leuven, Belgium.
- Department of Pathology, Radboud University Medical Center, Nijmegen, The Netherlands.
- Department of Neurosurgery, School for Mental Health and Neuroscience (MHeNS), Maastricht University Medical Center, Maastricht, The Netherlands.
- Academic Center for Epileptology, Maastricht University Medical Center and Kempenhaeghe, Maastricht-Heeze, The Netherlands.
ORCID-Profile: Maikel Verduin, Ann Hoeben, Marc A Vooijs
Förderung
- FWO
- KWF Kankerbestrijding
- Stichting STOPhersentumoren.nl
Zitieren
APA
Verduin, M., Hoosemans, L., Vanmechelen, M., van Heumen, M., Piepers, J. A. F., Astuti, G., Ackermans, L., Schijns, O. E. M. G., Kampen, K. R., Tjan-Heijnen, V. C. G., de Barbanson, B. A., Postma, A. A., Eekers, D. B. P., Broen, M. P. G., Beckervordersandforth, J., Staňková, K., de Smet, F., Rich, J., Hubert, C. G., …, & Vooijs, M. A. (2023). Patient-derived glioblastoma organoids reflect tumor heterogeneity and treatment sensitivity. Neuro-Oncology Advances, 5(1). https://doi.org/10.1093/noajnl/vdad152
Vancouver
Verduin M, Hoosemans L, Vanmechelen M, van Heumen M, Piepers JAF, Astuti G, et al. Patient-derived glioblastoma organoids reflect tumor heterogeneity and treatment sensitivity. Neuro-Oncology Advances. 2023;5(1). doi:10.1093/noajnl/vdad152
BibTeX
@article{Verduin2023,
author = {Verduin, Maikel and Hoosemans, Linde and Vanmechelen, Maxime and van Heumen, Mike and Piepers, Jolanda A F and Astuti, Galuh and Ackermans, Linda and Schijns, Olaf E M G and Kampen, Kim R and Tjan-Heijnen, Vivianne C G and de Barbanson, Buys A and Postma, Alida A and Eekers, Danielle B P and Broen, Martijn P G and Beckervordersandforth, Jan and Staňková, Katerina and de Smet, Frederik and Rich, Jeremy and Hubert, Christopher G and Gimenez, Gregory and Chatterjee, Aniruddha and Hoeben, Ann and Vooijs, Marc A},
title = {Patient-derived glioblastoma organoids reflect tumor heterogeneity and treatment sensitivity},
journal = {Neuro-Oncology Advances},
year = {2023},
volume = {5},
number = {1},
doi = {10.1093/noajnl/vdad152}
}
EUVIMED